US20070031482A1 - PDT treatment method for cellulites and cosmetic use - Google Patents

PDT treatment method for cellulites and cosmetic use Download PDF

Info

Publication number
US20070031482A1
US20070031482A1 US11/489,873 US48987306A US2007031482A1 US 20070031482 A1 US20070031482 A1 US 20070031482A1 US 48987306 A US48987306 A US 48987306A US 2007031482 A1 US2007031482 A1 US 2007031482A1
Authority
US
United States
Prior art keywords
photosensitizer
cellulite
area
treatment
reducing unwanted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/489,873
Other languages
English (en)
Inventor
Danilo Castro
Wolfgang Neuberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec Pharma Marketing Ltd
Ceramoptec Industries Inc
Original Assignee
Ceramoptec Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceramoptec Industries Inc filed Critical Ceramoptec Industries Inc
Priority to US11/489,873 priority Critical patent/US20070031482A1/en
Assigned to CERAMOPTEC INDUSTRIES, INC. reassignment CERAMOPTEC INDUSTRIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASTRO, DANILO, NEWBERGER, WOLFGANG
Priority to RU2008108009/14A priority patent/RU2444385C2/ru
Priority to CA2616461A priority patent/CA2616461C/en
Priority to JP2008525043A priority patent/JP2009503074A/ja
Priority to EP06813236.4A priority patent/EP1928466B1/en
Priority to ES06813236.4T priority patent/ES2659917T3/es
Priority to BRPI0614453A priority patent/BRPI0614453A8/pt
Priority to MX2008001547A priority patent/MX2008001547A/es
Priority to CN200680028493.3A priority patent/CN101568344B/zh
Priority to PCT/US2006/029284 priority patent/WO2007016287A2/en
Priority to AU2006275721A priority patent/AU2006275721B2/en
Priority to KR1020087005284A priority patent/KR101330120B1/ko
Assigned to CERAMOPTEC INDUSTRIES, INC. reassignment CERAMOPTEC INDUSTRIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASTRO, DANILO, NEUBERGER, WOLFGANG
Publication of US20070031482A1 publication Critical patent/US20070031482A1/en
Priority to IL189019A priority patent/IL189019A/en
Assigned to BIOLITEC PHARMA MARKETING LTD. reassignment BIOLITEC PHARMA MARKETING LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOLITEC, INC.
Priority to US12/899,003 priority patent/US8414880B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81—Preparation or application process involves irradiation

Definitions

  • the present invention relates to the field of cosmetic treatment and, in particular, relates to a photodynamic therapy treatment to remove cellulite tissue and also excess adipose cells in areas of the body prone to buildup of such tissues.
  • Edematous-fibrosclerotic panniculopathy is a medical term used to describe cellulite.
  • Cellulite affects 80-90% of women in their post-pubertal period. Cellulites are found commonly on the hips, thighs, and buttocks giving a dimpled appearance in those areas of the body. It is not a disorder but an issue of cosmetic concern to the individual. Cellulite is most often seen in women than in men due to the structural differences of their adipose tissue. Cellulite is not related to obesity or overweight, since it can occur even in normal and thin women.
  • Cellulite is different from fat cell layer in the body. Most fatty deposit in the individual depends on his/her weight, life style and genetic makeup. Fat layer in the body had important function of insulation, protecting vital organs etc. while cellulite is largely due to structural conformation below the skin which appears as lumpy pockets of trapped fat giving uneven dimpling or orange peel skin.
  • Lipodystrophies are produced because the adiposities have a hereditary genetic code which makes them evolve in a specific way.
  • Each adipocite cell has Beta 1 (lipogenetic) and Alfa 2 (lipolitic) receptors in its membrane. When there are more Beta 1 receptors on a particular area, then a localized obesity or lipodystrophy is produced. Because of the excessive Beta receptors in certain families, these families have a tendency for enlarged legs, breasts, waists, etc. On these patients treatment with low caloric diets exclusively is normally not successful which leads to abandonment of the treatment and recovering whatever localized fat was removed and returning to the same unhealthful practices.
  • U.S. Pat. No. 6,206,873 by Paolini, et al., titled, “Device and Method for Eliminating Adipose Layers by Means of Laser Energy,” discloses a hollow needle with an optical fiber in the center.
  • the fat tissue, adipose cells is liquidized when the cell walls are broken.
  • the fluid is removed by suction through the needle.
  • the laser is used to simply thermally degrade the cell walls.
  • Laser wavelength range is noted as from 0.75 to 2.5 microns but a preferred wavelength of 1.06 is called out.
  • a rounded optical fiber end is shown in FIG. 3 beyond the needle end.
  • Paolini et al. use a Nd:YAG type of laser and note a wavelength range above.
  • Paolini et al. further note that the liquid produced may be removed from the body by normal absorption.
  • Altshuler et al. disclose the removal of lipid rich tissue using external laser, a YAG source as well as other lasers whose output energy are in a wavelength range of 880 to 935 nm, 1150 to 1230 nm or 2280 to 2360 nm. It is noted that the radiation in the lower bands, specifically, 900 to 930, and 1150 to 1230, are preferred in the treatment of fat tissue. Specifically, wavelength regions near water/OH absorptions are identified as not preferred. Also they recommend the use of a cooling system.
  • U.S. Pat. No. 6,743,215 by Bernakei, titled, “Method and Apparatus for Skin Absorption Enhancement and Cellulite Reduction” discloses a process including the application of a compound upon an abraded skin surface followed by electrical and mechanical to remove cellulite.
  • PDT PhotoDynamic Therapy
  • the present invention provides a photosensitizer mixture and a method of treating cellulites by means of a percutaneous application of the mixture into the area of cellulite buildup followed by light illumination is presented.
  • the photosensitizer can be combined with one or more cellular products including adipose cells and/or collagen or hyaluronic acid or compounds that have been previously removed by liposuction.
  • This mixture can also include other compounds such as Lipofundin MCT 10% to improve the photosensitizer's diffusion or to dilute it Varying concentrations are used depending on the area of treatment as well as the stage of the cellulites and whether the cellulites present a depressed area in the skin or an elevated area.
  • the cosmetic treatment method substantially reduces or removes localized lipodystrophies and/or flaccidity and/or cellulite by localized laser, LED or other light irradiation of the area of treatment having a photosensitizer applied therein.
  • the light energy is applied to destroy the “fat” cells by a combination of chemical reactions, primarily, and temperature wherein the cell walls break releasing the cell fluid.
  • the light radiation is generally applied through devices to guide the radiation to the area of treatment.
  • One or more light sources such as laser diodes or LEDs may be coupled into one or more optical fibers to increase the area of coverage as well as increase the amount of radiation in that area of coverage.
  • Optical fibers can be introduced percutaneously or possibly interstitially into the area of treatment. Cell fluid in the area of treatment is removed by a combination of techniques. Quick and lasting cosmetic changes in areas having prior untreatable cellulite fat tissues are achieved while minimizing trauma.
  • FIGS. 1A and 1B illustrate the before and after treatment of a hip area within days after treatment of a first patient by the method/composition of the present invention
  • FIGS. 2A and 2B illustrate the before and after treatment of a lower buttock area within days after treatment of said first patient by the method/composition of the present invention
  • FIGS. 3A and 3B illustrate the before and after treatment of a thigh area within days after treatment of said first patient by the present invention
  • FIGS. 4A , and 4 B illustrate a second patient having cellulites in typical areas of the body
  • FIGS. 5A and 5B illustrate the second patient, after having treatment by the present invention, showing the absence of cellulites in these same typical areas.
  • FIG. 6 illustrate a third patient before treatment and then 1 month and 6 months after treatment by the method and composition of the present invention
  • FIG. 7 illustrates the process of Temoporfin interacting with cells.
  • FIG. 8 illustrates the chemical makeup of Temoporfin.
  • FIGS. 9A and 9B illustrate appropriate marking of sectors having cellulite thereon.
  • FIG. 10 to 16 presents before and after pictures, of varying days, of 8 female patients, ranging in age from 23 to 56 years initially having Stage II, III or IV cellulites which pictorially demonstrates the success of the present invention in reducing the stage of cellulites in each patient;
  • the goals of the present invention in regards to the treatment of cellulites is to: (1) provide a method of esthetic alterations of the skin for improving its visual aspect; (2) provide a process for homeostasis of the cells that are altered in the treatment of cellulites; and (3) increase of the web of collagen for optimizing the results of the adipose graft when treating cellulites.
  • suitable photosensitizers porphyrins and their derivatives including temoporfin, chlorins, bacteriopheophorbide, bacteriochlorins etc are used.
  • the selected photosensitizer can be administered using suitable delivery systems like liposomes, prodrug etc for efficient drug delivery to selected target cell.
  • photosensitizer is used to include precursors of photosensitizers, which naturally become photosensitizers after introduction into a patient as the precursor.
  • FIG. 1 to 6 present dramatic evidence of the success of the present invention in substantially reducing the effects and appearance of cellulites in three patients after only 1 or several treatments and only a few days after the treatments.
  • the photosensitizer Temoporfin When the photosensitizer Temoporfin is activated with light from a diode laser, e.g., 652 nm wavelength, this produces an intracellular oxidation that is believed to act to modify the cell membrane's properties, the cytoplasm, ribosomas, Golgi's appliance, and nucleus, eventually triggering a series of events that result with the cell apostosis.
  • a diode laser e.g. 652 nm wavelength
  • the cell is ingested by phagocytosis or by nearby cells avoiding the inflammatory response typical during normal cell necrosis. Even though the cell disappears, there is an increase of the collagen web. This improves the support of collagen, realignment of the collagen fibers and elastin, decreases the gelatinous consistency of the fundamental inter-cell substance, improves oxygenation and cell nutrition, and decreases toxic metabolites' retention and the edema.
  • Temoporfin is a very efficient generator of active oxygen which does not require a large dose of the drug nor a long exposure to light.
  • FIG. 7 illustrates the process of Temoporfin's interaction upon activation.
  • the intracellular oxidation is responsible for the alterations of the membrane's surface and the nuclear, the mitocondrias, Golgi's appliance, the net endoplasmatic and the ribosomas resulting in the death of the cells or cell apoptosis.
  • Temoporfin in the past has been used in the treatment of some head and neck cancers.
  • Temoporfin is totally innocuous and inactive in the dark and is activated with low intensities of light and it turns into a powerful isolated-oxygen generator.
  • a patient having cellulites is treated with Temoporfin in several sessions.
  • a concentration of 0.005 mg/ml is applied directly by Mesotherapy. This concentration results from the study of optimal concentrations for the use of m-THPC on the treatment of tumors: 0.1 to 0.3 micrograms per gram of tumor tissue.
  • the aesthetic doses are 10 times lower as the objective is to develop a collagen matrix and not destroy a tumor. Therefore, the aesthetic doses range from 5 to 15 ⁇ g/50 gr of cellulites tissues.
  • 2 cc of Mesotherapy solution must contain 0.005 to 0.015 mg of m-THPC so its concentration must be as follows: Concentration of M-THPC for Mesotherapy on cellulites: 0.005 mg/ml to 0.01 mg/ml.
  • CONTACT THERMOGRAPHY may be used.
  • High Resolution Contact Thermography is ideal to accomplish classification of the grade of cellulites and patient tracking during treatment since small variations are evidenced during treatment.
  • This process measures the superficial temperature of the skin surface when placed in contact therewith by means of a plate of capsulated liquid crystals.
  • the color of the crystals is an indication of the temperature of the underlying skin.
  • the brown colors mark hypothermic zones with little circulation and the blue colors indicate hypothermic zones with increased circulation.
  • the temperatures are registered on the skin and provide 3 or 4 grades of temperatures of the hypodermis.
  • the homogeneous imagery indicates the condition of the cellulites and provides exactness of diagnosis, topography and the cellulites stage. The following are examples of imagery from cellulites areas as well as the stages associated with that cellulites:
  • a reference termography may be done on the arm or on the forearm zones that in general do not present cellulites.
  • Stages I and II Slowing down of the venous and lymphatic circulation; with the dilatation of the little veins of the deep cape of the dermis. Interstitial edema at zones surround the adipose cells. The exudation increases rapidly for the serum from the capillaries of the subcutaneous tissue. The zone with edema compresses the conjunctive fibers as well as the nervous elements, and it can manifest itself with pain by touch and at times spontaneous. There may be alterations of sensibility and formation of stretch marks.
  • Thermography in these stages presents hyperthermic big and diffuse borders, surrounded stains evidence hypodermic diffuse zones and the image translates the alteration and instability of the microcirculation of the zone.
  • Stage III there is fibrous proliferation.
  • the fibers swell up and there is a decrease of collagen, an increase in the fibrin and loss of the individual characteristics of little fibers that mask a named fibrinoide type.
  • Collagen is deconstructed and degenerated, forming irregular, amorphous blocks, losing its structure and provoking confinement of the full adipositos of tri-glycerides.
  • the clinical and visual aspect is termed the “orange skin.”
  • There is slowing down of cell vascular interchanges thus forming micronodules. The reversibility of the effect becomes more difficult in this phase.
  • Thermography evidence The image is a multi-colored image where the predominate colors are celestial green and pink.
  • Leopard's aspect of the skin localizes the irregularities of temperature in the skin for effect of the micronodules.
  • the very cold zones that the black announces begin to appear as “Black Holes” which characterize stage IV cellulite.
  • Stage IV The fibrosis increases and compresses veins and nerves producing an alteration of the elements of the conjunctive tissue.
  • the adipose tissue is divided into compartments like tablets with large hypothermic blocks because of its low sanguine circulation.
  • the adipocytes are normal, but they are compressed.
  • Several contiguous intervening micronodules fuse as one capsule making a macronodule that is palpable.
  • the image presents one of Black Holes with extensive hypodermic zones that indicate that macronodules are presence.
  • the patient is administered the Temoporfin solution as follows: In all sequences, the treatment consists 1 session only per area to be treated, and, if necessary, it is repeated in 30 days. In general, it was observed that only 1 session followed by appropriate physiotherapy, a complementary session (like ultrasound, lymph-drainage, isotonic and isometric electro-stimulation), was usually sufficient in more than 80% of the patients. If it was necessary to repeat it, an evaluation is done after 30 days.
  • a complementary session like ultrasound, lymph-drainage, isotonic and isometric electro-stimulation
  • Table 2 presents further information as to the stage of cellulite, concentration of mTHPC (Temoporfin), dose, surface area being treated; strength, power level and time of laser radiation application.
  • the PDT's application TEMOPORFIN will follow the following parameters CELLULITIS M - THPC DOSE SURFACE LATENCY Watts TIME PDT I HARROW I II 0.1 mg/ml 10 cc 600 cm2 (20 ⁇ 30) 30′ 2 W 2′ each 100 cm2 I HARROW III 0.2 mg/ml 10 cc 600 cm2 (20 ⁇ 30) 30′ 2 W 2′ each 100 cm2 I HARROW IV 0.2 mg/ml 10 cc 400 cm2 (20 ⁇ 20) 30′ 2.5 W 3′ each 100 cm2
  • thermographic images Accomplish a mapping with sectorial (See FIG. 9 ) thermographic images and the recording of this information as to each patient for reference during treatment;
  • thermography noting cold zones, micro-nodules and black holes.
  • the patient's body should be divided into sectors with the stage level noted for each. This is beneficial for followup treatments and consultation. Pictures of a body are included noting the different sector numbers.
  • Temoporfin Because of the low dose concentration of Temoporfin, the cost should be low so that it will be affordable.
  • Lipofundin MCT 10% may be applied in the tissue with there is cellulites to improvement the Temoporfin's diffusion. Further, Lipofundin may be used to dilute the Temoporfin.
  • Temoporfin is a photosensitizer from a group that have affinity to phospholipids and cell membranes but are not soluble in triglycerides.
  • the diluted Temoporfin (formulated in a liposome) is mixed 0.3 mg per ml;
  • fat from liposuction is washed and mixed with the diluted temoporfin at a ratio 5 parts to 1 part;
  • a mesotherapy with Temoporfin (formulated in a liposome) having 0.3 mg per ml was diluted.
  • the procedure is as follows: 1. analysis and marking off of areas to be treated; 2. adding fluid to areas, after local anesthetic applied; 3. lasing of tissue within each area of treatment; 4. squeeze and suction of melted fat; and 5. application of ointments, etc., after treatments.
  • Temoporfin (formulated in a liposome) Mesotherapy deep injection:
  • Lymph-drainage/soft massage This helps to distribute the drug within the area of treatment
  • FIGS. 10 through 16 present examples of patients before and after treatment.
  • the cellulite is staged by clinical impression and by thermography.
  • Liposomal formulation of temoporfin diluted in 5% gluocuse solution is used.
  • Diluted liposomal formulated temoporfin (1 part) is mixed with lipofundin (9 part) which helps better drug diffusion into the cellulite.
  • Pistol like device with trigger is used for injecting the drug into the treatment site.
  • Single shot using the device delivers 12 ⁇ l of liposomal formulated temoporfin; each injection site receives two such shots to a depth of 0.5 cm.
  • Each injection site is separated from each other by 0.5 cm approximately. Dose of the drug can be increased based on the cellulite stage which needs to be treated.
  • Illumination is performed using LED arrays (area of the array is 4*4 cm) with wavelength 652 nm, power density 180 mW/cm 2 .
  • Treatment schedule 4 LED treatments are performed in the patient. The first starts 48 h after injection of the liposomal formulated temoporfin. The second, third and fourth are performed on 7, 14 and 21 days after injection respectively.
  • photosensitizers For the sake of this invention and particularly for the claims, some precursors of photosensitizers become photosensitizers by the natural activity of the animal injected with them. These are considered, therefore to be included within the general word, “photosensitizers” used in the claims and general specification, as was noted earlier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
US11/489,873 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use Abandoned US20070031482A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US11/489,873 US20070031482A1 (en) 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use
KR1020087005284A KR101330120B1 (ko) 2005-08-02 2006-07-27 셀룰라이트 및 미용 용도를 위한 ｐｄｔ 처리 방법
CN200680028493.3A CN101568344B (zh) 2005-08-02 2006-07-27 用于治疗橙皮脂肪组织的光敏剂混合物
AU2006275721A AU2006275721B2 (en) 2005-08-02 2006-07-27 PDT treatment method for cellulites and cosmetic use
JP2008525043A JP2009503074A (ja) 2005-08-02 2006-07-27 セルライトに対する光力学療法および美容法
EP06813236.4A EP1928466B1 (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulite and cosmetic use
ES06813236.4T ES2659917T3 (es) 2005-08-02 2006-07-27 Método de tratamiento de terapia fotodinámica (TFD) para celulitis y uso cosmético
BRPI0614453A BRPI0614453A8 (pt) 2005-08-02 2006-07-27 Método de redução de celulite indesejada em áreas seletivas de um organismo e mistura fotossensibilizante
MX2008001547A MX2008001547A (es) 2005-08-02 2006-07-27 Metodo de tratamiento de pdt para celulitis y uso cosmetico.
RU2008108009/14A RU2444385C2 (ru) 2005-08-02 2006-07-27 Способ фотодинамической терапии для лечения целлюлитов и косметического использования
PCT/US2006/029284 WO2007016287A2 (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulites and cosmetic use
CA2616461A CA2616461C (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulites and cosmetic use
IL189019A IL189019A (en) 2005-08-02 2008-01-24 Cosmetic treatment method to reduce cellulite in selected areas of the person and a mixture that increases light sensitivity for cellulite tissue treatment
US12/899,003 US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70479705P 2005-08-02 2005-08-02
US11/489,873 US20070031482A1 (en) 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/899,003 Continuation-In-Part US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use
US12/899,003 Continuation US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Publications (1)

Publication Number Publication Date
US20070031482A1 true US20070031482A1 (en) 2007-02-08

Family

ID=37709188

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/489,873 Abandoned US20070031482A1 (en) 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use
US12/899,003 Expired - Fee Related US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/899,003 Expired - Fee Related US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Country Status (13)

Country Link
US (2) US20070031482A1 (ko)
EP (1) EP1928466B1 (ko)
JP (1) JP2009503074A (ko)
KR (1) KR101330120B1 (ko)
CN (1) CN101568344B (ko)
AU (1) AU2006275721B2 (ko)
BR (1) BRPI0614453A8 (ko)
CA (1) CA2616461C (ko)
ES (1) ES2659917T3 (ko)
IL (1) IL189019A (ko)
MX (1) MX2008001547A (ko)
RU (1) RU2444385C2 (ko)
WO (1) WO2007016287A2 (ko)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
WO2008088810A2 (en) * 2007-01-18 2008-07-24 Ceramoptec Industries Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080214460A1 (en) * 2007-01-18 2008-09-04 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
US20080248554A1 (en) * 2005-12-02 2008-10-09 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US8753339B2 (en) 2005-09-07 2014-06-17 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9272124B2 (en) 2005-12-02 2016-03-01 Ulthera, Inc. Systems and devices for selective cell lysis and methods of using same
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US11123280B2 (en) * 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
US11879141B2 (en) 2012-01-12 2024-01-23 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase II and methods of producing the same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050171B2 (en) * 2010-10-04 2015-06-09 William J. Foster Small diameter fragmatome for minimally traumatic retained lens fragments removal
ES2647895T3 (es) * 2012-09-07 2017-12-27 Shiseido Company Ltd. Método para evaluar la celulitis y método para evaluar la eficacia de un fármaco contra la celulitis empleando fibulina-3 y/o sarcoglicano gamma como indicador
US10143521B2 (en) * 2013-03-22 2018-12-04 Koninklijke Philips N.V. Skin treatment apparatus
WO2015069629A1 (en) * 2013-11-06 2015-05-14 Terry Ward Cellulite and fat reducing device and method utilizing optical emitters
RU2565373C9 (ru) * 2014-05-20 2016-09-20 Медицинский Центр Высоких Технологий "Лазервита" Способ восстановления структуры кожи лица и шеи
RU2576788C1 (ru) * 2015-04-07 2016-03-10 Екатерина Евгеньевна Фаустова Способ комплексного восстановления и поддержания состояния кожи, подкожно-жировой клетчатки, мышечной и соединительной ткани в косметологии (варианты)
CZ307681B6 (cs) 2016-02-29 2019-02-13 Ústav makromolekulární chemie AV ČR, v. v. i. Fotoaktivovatelná nanočástice pro fotodynamické aplikace, způsob její přípravy, farmaceutická kompozice ji obsahující a jejich použití
US11083879B2 (en) * 2017-03-29 2021-08-10 Vanessa White Vaginal detoxing kit and method
EP3556342A1 (en) 2018-04-17 2019-10-23 Acpac Biotech, S.L. Cosmetic multilevel method for cellulite and/or skin flaccidity
RU2700102C1 (ru) * 2018-10-01 2019-09-12 Общество с ограниченной ответственностью Центр пластической хирургии и косметологии "Шарм" Способ комбинированной липосакции
RU2705625C1 (ru) * 2019-01-10 2019-11-11 Александр Александрович Игумнов Способ удаления подкожно-жировой ткани в области плеча
CN111956643B (zh) * 2020-09-15 2024-06-25 西安交通大学 维替泊芬用于制备肥胖症药物的应用
RU2753666C1 (ru) * 2021-03-01 2021-08-19 Зоя Александровна Евсюкова Способ лечения гиноидной липодистрофии

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5743215A (en) * 1996-09-30 1998-04-28 Zeff; Jack D. Cat toy for reliably triggering play or attack behavior
US5807385A (en) * 1993-08-02 1998-09-15 Keller; Gregory S. Method of laser cosmetic surgery
US6074666A (en) * 1992-02-05 2000-06-13 Qlt Phototherapeutics, Inc. Liposome compositions of porphyrin photosensitizers
US6206873B1 (en) * 1996-02-13 2001-03-27 El. En. S.P.A. Device and method for eliminating adipose layers by means of laser energy
US20010056294A1 (en) * 2000-05-19 2001-12-27 Ushio Denki Kabushiki Kaisya Discharge lamp for photodynamic therapy and photodynamic diagnosis
US6605080B1 (en) * 1998-03-27 2003-08-12 The General Hospital Corporation Method and apparatus for the selective targeting of lipid-rich tissues
US20050215524A1 (en) * 2004-02-12 2005-09-29 Ceramoptec Industries, Inc. Methods and compositions for improving photodynamic therapy through administration of lipids
US20060035952A1 (en) * 2004-08-16 2006-02-16 Ceramoptec Industries, Inc. Photosensitizer formulations and their use
US7354599B2 (en) * 2003-08-26 2008-04-08 Ceramoptec Industries, Inc. Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454842B (sv) * 1984-11-01 1988-06-06 Pharmacia Ab Komposition for anvendning vid oftalmologiska applikationer innehallande en vattenlosning av en hogmolekyler polymer och ett lost polymert fergemne
US5484778C1 (en) * 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
US5587396A (en) * 1994-08-26 1996-12-24 Mary Kay Inc. Method of ameliorating cellulite by disrupting the barrier function of the stratum corneum
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
IT1279011B1 (it) * 1995-06-15 1997-12-02 Ips Int Prod Services Apparecchiatura per la rilevazione e scelta dei trattamenti della cellulite
IL114459A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Method for detecting and/or monitoring the effectiveness of treatment of T cell mediated diseases
FR2767704A1 (fr) * 1997-09-04 1999-02-26 Medlight Sa Dispositif diffuseur de lumiere pour le traitement photodynamique d'organes
US6120987A (en) * 1997-12-12 2000-09-19 Cis Bio International Non-aggregated fluorescent conjugates and the process for their preparation
EP0911023A1 (en) 1998-03-20 1999-04-28 Mario Luca Russo Pharmaceutical or cosmetic compositions containing photosensitizing substances
US20020004053A1 (en) * 1998-08-25 2002-01-10 Biel Merrill A. Cellular or acellular organism eradication via photodynamic activation of a cellular or acellular organism specific immunological response
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
JP2002200181A (ja) * 2000-10-31 2002-07-16 Shigehiro Kubota レーザ治療装置
DE10107575A1 (de) * 2001-02-06 2002-08-08 Beate Roeder Verfahren zur Fett-und Gewichtsreduktion im menschlichen oder tierischen Organismus durch Nutzung des photodynamischen Effekts
US6743215B2 (en) 2001-04-06 2004-06-01 Mattioli Engineering Ltd. Method and apparatus for skin absorption enhancement and cellulite reduction
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US20040232169A1 (en) * 2003-05-23 2004-11-25 Alberto-Culver Company Dispenser and related dispensing method
JP2005008565A (ja) * 2003-06-19 2005-01-13 Naris Cosmetics Co Ltd 痩身化粧料
CA2529953A1 (en) * 2003-06-23 2004-12-29 Transpharma Medical Ltd. Transdermal delivery system for cosmetic agents
US7754798B2 (en) * 2003-08-28 2010-07-13 Cryovac, Inc. Oxygen scavenger block copolymers and compositions
US20050085455A1 (en) * 2003-10-16 2005-04-21 Light Sciences Corporation Photodynamic therapy for local adipocyte reduction
US7416519B2 (en) * 2004-07-20 2008-08-26 Heck Robert W Massage and resistance training apparatus and method
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
FR2941151B1 (fr) * 2009-01-22 2012-05-11 Caster Extrait de lentinus pour son action sur la cellulite et les amas graisseux.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US6074666A (en) * 1992-02-05 2000-06-13 Qlt Phototherapeutics, Inc. Liposome compositions of porphyrin photosensitizers
US5807385A (en) * 1993-08-02 1998-09-15 Keller; Gregory S. Method of laser cosmetic surgery
US6206873B1 (en) * 1996-02-13 2001-03-27 El. En. S.P.A. Device and method for eliminating adipose layers by means of laser energy
US5743215A (en) * 1996-09-30 1998-04-28 Zeff; Jack D. Cat toy for reliably triggering play or attack behavior
US6605080B1 (en) * 1998-03-27 2003-08-12 The General Hospital Corporation Method and apparatus for the selective targeting of lipid-rich tissues
US20010056294A1 (en) * 2000-05-19 2001-12-27 Ushio Denki Kabushiki Kaisya Discharge lamp for photodynamic therapy and photodynamic diagnosis
US7354599B2 (en) * 2003-08-26 2008-04-08 Ceramoptec Industries, Inc. Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy
US20050215524A1 (en) * 2004-02-12 2005-09-29 Ceramoptec Industries, Inc. Methods and compositions for improving photodynamic therapy through administration of lipids
US20060035952A1 (en) * 2004-08-16 2006-02-16 Ceramoptec Industries, Inc. Photosensitizer formulations and their use

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US9364246B2 (en) 2005-09-07 2016-06-14 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8366643B2 (en) 2005-09-07 2013-02-05 Cabochon Aesthetics, Inc. System and method for treating subcutaneous tissues
US8753339B2 (en) 2005-09-07 2014-06-17 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9005229B2 (en) 2005-09-07 2015-04-14 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9248317B2 (en) 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080248554A1 (en) * 2005-12-02 2008-10-09 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US9272124B2 (en) 2005-12-02 2016-03-01 Ulthera, Inc. Systems and devices for selective cell lysis and methods of using same
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US20080214460A1 (en) * 2007-01-18 2008-09-04 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
WO2008088810A3 (en) * 2007-01-18 2008-12-18 Ceramoptec Ind Inc Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
WO2008088810A2 (en) * 2007-01-18 2008-07-24 Ceramoptec Industries Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
US20110021973A1 (en) * 2007-01-18 2011-01-27 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
WO2009005995A1 (en) * 2007-06-29 2009-01-08 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US10220122B2 (en) 2007-10-09 2019-03-05 Ulthera, Inc. System for tissue dissection and aspiration
US9039722B2 (en) 2007-10-09 2015-05-26 Ulthera, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US9044259B2 (en) 2009-08-07 2015-06-02 Ulthera, Inc. Methods for dissection of subcutaneous tissue
US10271866B2 (en) 2009-08-07 2019-04-30 Ulthera, Inc. Modular systems for treating tissue
US8979881B2 (en) 2009-08-07 2015-03-17 Ulthera, Inc. Methods and handpiece for use in tissue dissection
US8920452B2 (en) 2009-08-07 2014-12-30 Ulthera, Inc. Methods of tissue release to reduce the appearance of cellulite
US8906054B2 (en) 2009-08-07 2014-12-09 Ulthera, Inc. Apparatus for reducing the appearance of cellulite
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US8900261B2 (en) 2009-08-07 2014-12-02 Ulthera, Inc. Tissue treatment system for reducing the appearance of cellulite
US8900262B2 (en) 2009-08-07 2014-12-02 Ulthera, Inc. Device for dissection of subcutaneous tissue
US9510849B2 (en) 2009-08-07 2016-12-06 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US9757145B2 (en) 2009-08-07 2017-09-12 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8894678B2 (en) 2009-08-07 2014-11-25 Ulthera, Inc. Cellulite treatment methods
US9078688B2 (en) 2009-08-07 2015-07-14 Ulthera, Inc. Handpiece for use in tissue dissection
US10485573B2 (en) 2009-08-07 2019-11-26 Ulthera, Inc. Handpieces for tissue treatment
US10531888B2 (en) 2009-08-07 2020-01-14 Ulthera, Inc. Methods for efficiently reducing the appearance of cellulite
US11337725B2 (en) 2009-08-07 2022-05-24 Ulthera, Inc. Handpieces for tissue treatment
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US10603066B2 (en) 2010-05-25 2020-03-31 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US11213618B2 (en) 2010-12-22 2022-01-04 Ulthera, Inc. System for tissue dissection and aspiration
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US11879141B2 (en) 2012-01-12 2024-01-23 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase II and methods of producing the same
US11975054B2 (en) 2012-01-12 2024-05-07 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase I and methods of producing the same
US11123280B2 (en) * 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
US11813347B2 (en) 2017-03-01 2023-11-14 Endo Ventures Limited Method of assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase

Also Published As

Publication number Publication date
JP2009503074A (ja) 2009-01-29
RU2008108009A (ru) 2009-09-10
EP1928466A4 (en) 2012-12-19
WO2007016287A2 (en) 2007-02-08
US8414880B2 (en) 2013-04-09
IL189019A (en) 2013-10-31
CN101568344B (zh) 2014-06-11
RU2444385C2 (ru) 2012-03-10
BRPI0614453A2 (pt) 2012-12-11
KR20080039968A (ko) 2008-05-07
AU2006275721A1 (en) 2007-02-08
BRPI0614453A8 (pt) 2016-10-11
ES2659917T3 (es) 2018-03-20
WO2007016287A9 (en) 2008-10-30
MX2008001547A (es) 2008-09-11
EP1928466A2 (en) 2008-06-11
AU2006275721B2 (en) 2012-11-29
US20110152745A1 (en) 2011-06-23
CN101568344A (zh) 2009-10-28
KR101330120B1 (ko) 2013-11-15
EP1928466B1 (en) 2017-11-22
IL189019A0 (en) 2008-08-07
WO2007016287A3 (en) 2008-12-18
CA2616461A1 (en) 2007-02-08
CA2616461C (en) 2013-10-01

Similar Documents

Publication Publication Date Title
CA2616461C (en) Pdt treatment method for cellulites and cosmetic use
Fijan et al. Photodynamic therapy of epithelial skin tumours using delta‐aminolaevulinic acid and desferrioxamine
Klein et al. Photodynamic therapy in dermatology–an update 2008
US6723750B2 (en) Photodynamic therapy for pre-melanomas
Harth et al. Modified Topical Photodynamic Therapy of Superficial Skin Tumors, Utilizing Aminolevulinic Acid, Penetration Enhancers, Red Light, and Hypertherntia
US20110020252A1 (en) Method of long lasting human skin tanning
EP2131862B1 (en) Fuid photosensitizer for therapeutic photodynamic skin treatment and its use in non therapeutic photodynamic skin treatments
Fritsch et al. Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods
US20100255080A1 (en) Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
Mitra et al. Topical photodynamic therapy for non-cancerous skin conditions
Silva et al. Photodynamic therapy: dermatology and ophthalmology as main fields of current applications in clinic
US20070154538A1 (en) Removal of fat cells by PDT
Ziolkowski et al. Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture.
Peterson et al. Photodynamic therapy
Li et al. Advances In Photodynamic Therapy of Pathologic Scar
Andrejevic-Blant et al. Interstitial photodynamic therapy with tetra (m-hydroxyphenyl) chlorin: tumor versus striated muscle damage
Alvanopoulos et al. Photodynamic therapy of superficial basal cell carcinomas using exogenous 5‐aminolevulinic acid and 514‐nm light
Lee et al. A case of Bowen's disease partially responded to photodynamic therapy
Wanner et al. Lasers for Adipose Tissue and Cellulite
Garretson et al. Photodynamic Therapy and Inflammatory Disorders
Omi et al. Iontophoresis-enhanced cutaneous absorption of 5-aminolevulinic acid shortens the incubation period in photodynamic therapy
Bartoli Photodynamic Therapy in Skin Treatment
Gold The use of photodynamic therapy in the treatment of actinic keratoses and photorejuvenation
Plewig Indexed in: EMBASE, EMNursing, Compendex, GEOBASE
Goldman et al. 10 Photodynamic therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: CERAMOPTEC INDUSTRIES, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CASTRO, DANILO;NEWBERGER, WOLFGANG;REEL/FRAME:018221/0535

Effective date: 20060712

AS Assignment

Owner name: CERAMOPTEC INDUSTRIES, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CASTRO, DANILO;NEUBERGER, WOLFGANG;REEL/FRAME:018250/0619;SIGNING DATES FROM 20060712 TO 20060824

AS Assignment

Owner name: BIOLITEC PHARMA MARKETING LTD., MALAYSIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOLITEC, INC.;REEL/FRAME:022482/0944

Effective date: 20090331

Owner name: BIOLITEC PHARMA MARKETING LTD.,MALAYSIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOLITEC, INC.;REEL/FRAME:022482/0944

Effective date: 20090331

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION